Levosimendan interacts with potassium channel blockers in human saphenous veins

Basic & Clinical Pharmacology & Toxicology
J HõhnJ G Papp

Abstract

The involvement of potassium channels in the venodilating capacity of the inodilator levosimendan in human saphenous vein preparations was investigated. Levosimendan caused relaxation with 50% effective concentration (EC50) of 0.32 +/- 0.04 microM in isolated veins contracted by 5-hydroxytryptamine. Fifteen microM glibenclamide, a blocker of the ATP-sensitive potassium channels (K(ATP)), partially inhibited the relaxing effect of the inodilator. In the presence of iberiotoxin, the selective blocker of large conductance calcium-activated potassium channels (BK(Ca)), levosimendan induced contraction with EC50 of 0.21 +/- 0.06 microM. We presume that levosimendan dilates human saphenous veins by interacting with hyperpolarizing potassium channels (K(ATP) and BK(Ca)).

References

Jul 1, 1990·The American Journal of Physiology·M T NelsonN B Standen
Aug 1, 1995·Naunyn-Schmiedeberg's Archives of Pharmacology·J L BalwierczakS Hu
Sep 1, 1995·Journal of Molecular and Cellular Cardiology·H HaikalaI B Lindén
May 21, 1998·Journal of Cardiovascular Pharmacology·N GruhnJ Aldershvile
Jul 23, 2002·Lancet·F FollathUNKNOWN Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study
Sep 17, 2003·Cardiovascular Drugs and Therapy·János PatariczaJulius Gyula Papp
Oct 18, 2003·Cardiovascular Drugs and Therapy·Hisashi Yokoshiki, Nicholas Sperelakis

❮ Previous
Next ❯

Citations

Mar 24, 2006·Cardiovascular Drugs and Therapy·Sadi S OzdemCoskun Usta
Aug 19, 2007·Cardiovascular Drugs and Therapy·Fatma AkarSalih Fehmi Katircioglu
Oct 15, 2009·Cardiovascular Drugs and Therapy·Hossein MirkhaniHajar Khazraei
Sep 22, 2009·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Andis Graudins
Sep 25, 2008·European Journal of Pediatrics·Wilhelm Alexander OsthausRobert Sümpelmann
Jul 12, 2008·Expert Opinion on Investigational Drugs·John T ParissisDimitrios T Kremastinos
Aug 30, 2012·Scandinavian Cardiovascular Journal : SCJ·Matti KivikkoAlexandre Mebazaa
May 16, 2009·Pharmacological Reports : PR·Bilsen Eksert, Coşkun Usta
Mar 17, 2007·Pharmacology & Therapeutics·Charalambos AntoniadesChristodoulos Stefanadis
May 4, 2005·Cardiovascular Drug Reviews·Zoltán PappIstván Edes
Sep 14, 2007·Acta Anaesthesiologica Scandinavica·F GuarracinoC Vullo
Apr 25, 2006·The Annals of Thoracic Surgery·Oguzhan YildizCahit Nacitarhan
Jun 15, 2010·American Journal of Obstetrics and Gynecology·Mark P HehirJohn J Morrison
Mar 31, 2012·International Journal of Cardiology·Eftychios SiniorakisSotiria Limberi
Feb 3, 2015·European Journal of Pharmacology·Jouko LevijokiAntti Haapalinna
Apr 25, 2007·Journal of Pharmacological Sciences·Oguzhan Yildiz
May 16, 2006·Journal of the Society for Gynecologic Investigation·Oguzhan YildizMelik Seyrek
Jan 8, 2010·Regional Anesthesia and Pain Medicine·Juha AittomäkiPer H Rosenberg
Nov 30, 2018·Journal of Cardiovascular Pharmacology·Antoine HerpainFabio Sangalli
Apr 30, 2008·Current Opinion in Anaesthesiology·Bernardo Bollen PintoMartin Westphal
Mar 2, 2006·Anesthesiology·Wolfgang G Toller, Christian Stranz
Jul 30, 2019·Journal of Cardiovascular Pharmacology·Zoltán MártonJulius Gy Papp
May 3, 2014·Journal of Cardiovascular Pharmacology·László NagyZoltán Papp
Mar 9, 2005·Critical Care Medicine·Raúl J GazmuriIyad M Ayoub
Jan 26, 2012·European Journal of Anaesthesiology·Kamen P Valchanov, Joseph E Arrowsmith
Oct 31, 2021·ESC Heart Failure·Daniel BurkhoffZoltán Papp

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.